Fast track — ArticlesAdjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
Introduction
The International Agency for Research on Cancer reported 1·2 million cases of lung cancer worldwide in 2000, with 1·1 million deaths.1 Despite surgery, about 40% of patients with stage I non-small-cell lung cancer (NSCLC), 60% of patients with stage II disease, and 75% of patients with stage IIIA disease die within 5 years.2, 3 In 1995, a meta-analysis4 showed a non-significant 5% survival advantage at 5 years with cisplatin-based adjuvant chemotherapy in resected NSCLC compared with surgery alone. This finding prompted the planning of additional randomised trials.5 The International Adjuvant Lung Trial (IALT)6 showed a significant 4% benefit at 5 years for cisplatin-based chemotherapy in combination with various agents after curative surgery in stage I–III NSCLC. The Adjuvant Lung Cancer Project Italy (ALPI)7 did not find a survival benefit for chemotherapy, although the study used a toxic regimen. Subset analysis by stage showed that the hazard ratio of death was 0·80 (95% CI 0·60–1·06) for stage II versus 0·97 (0·71–1·33) and 1·06 (0·82–1·38) for stages I and III, respectively. The Cancer and Leukemia Group B (CALGB) 9633 study8 reported a 12% reduction in mortality at 4 years with adjuvant carboplatin plus paclitaxel in stage IB NSCLC, and an update8 with extended follow-up (54 vs 34 months) showed that improvement in survival was no longer significant. The National Cancer Institute of Canada JBR.10 trial9 showed a 15% improvement in overall survival for stage IB–II NSCLC treated with vinorelbine plus cisplatin. The subset analysis by stage showed a greater benefit at 5 years for stage II (20%) than for stage I (7%); at 6 years, the benefit for stage I disappeared, and survival was greater in the control group. In 1994, the Adjuvant Navelbine International Trialist Association (ANITA) initiated a randomised phase III trial in patients with completely resected stage IB, II, and IIIA NSCLC, to assess the survival benefit of adjuvant vinorelbine plus cisplatin versus control.
Section snippets
Patients
This open-label study was done in 101 centres in 14 countries. It was approved by the ethics committee of every centre and undertaken according to the Declaration of Helsinki. Written informed consent was obtained for all patients. Eligibility criteria included: histologically proven primary NSCLC (apart from bronchoalveolar carcinoma) after examination of the resected tumour by institution pathologist, and pathological TNM (tumour, node, metastasis) staging. Patients were eligible if they had
Results
From December, 1994, to December, 2000, 840 patients were enrolled in the trial: 407 were assigned to chemotherapy and 433 to observation (figure 1). On Aug 1, 2004, median potential follow-up was 76 months (range 43–113) in the chemotherapy group and 77 months (43–116) in the observation group.
Table 1 shows the patients' characteristics. Overall, 486 (58%) patients had a lobectomy and 310 (37%) a pneumonectomy; 325 (39%) had postoperative stage IIIA disease, 203 (24%) had stage II disease, and
Discussion
In this trial, we showed that the combination of vinorelbine and cisplatin significantly improved overall survival in patients with stages IB–IIIA NSCLC. However, our subgroup analysis indicated that the benefit is seen mainly in patients with stage II and IIIA disease.
Analysis took place after 458 patients had died instead of the planned 466; the steering committee allowed the analysis at this point, judging that the difference of eight deaths would not affect the results. Because of
References (17)
Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances
Hematol Oncol Clin N Am
(2005)- et al.
Weekly vinorelbine plus cisplatin versus day 1+8 vinorelbine with cisplatin in advanced non small-cell lung cancer: end results of a phase III trial
Lung Cancer
(2005) - et al.
Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis
J Thorac Cardiovasc Surg
(2004) - et al.
Estimating the world cancer burden: Globoscan 2000
Int J Cancer
(2001) - et al.
Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report
Cancer
(1999) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
BMJ
(1995)- et al.
Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer
Clin Cancer Res
(2005) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
N Engl J Med
(2004)
Cited by (1449)
The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis
2024, JTO Clinical and Research ReportsNew systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe
2024, The Lancet Regional Health - Europe